• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib.

作者信息

Agrawal Diksha, Sardana Kabir, Mathachan Sinu R, Ahuja Arvind

机构信息

Department of Dermatology, Venereology and Leprosy, Swami Dayanand Hospital, New Delhi, India.

Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi, India.

出版信息

Indian Dermatol Online J. 2023 May 25;14(4):564-566. doi: 10.4103/idoj.idoj_508_22. eCollection 2023 Jul-Aug.

DOI:10.4103/idoj.idoj_508_22
PMID:37521237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10373826/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cee/10373826/7c3f23c3c9cc/IDOJ-14-564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cee/10373826/1474f83655e2/IDOJ-14-564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cee/10373826/7c3f23c3c9cc/IDOJ-14-564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cee/10373826/1474f83655e2/IDOJ-14-564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5cee/10373826/7c3f23c3c9cc/IDOJ-14-564-g002.jpg

相似文献

1
A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib.一例伴有STAT 3和STAT 6表达增强的顽固性结节性痒疹及其对托法替布的显著反应
Indian Dermatol Online J. 2023 May 25;14(4):564-566. doi: 10.4103/idoj.idoj_508_22. eCollection 2023 Jul-Aug.
2
Tofacitinib for Prurigo Nodularis: A Case Report.托法替布治疗结节性痒疹：一例报告
Clin Cosmet Investig Dermatol. 2022 Mar 21;15:503-506. doi: 10.2147/CCID.S354025. eCollection 2022.
3
Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression.用托法替布治疗顽固性小儿结节性痒疹，这是JAK-STAT表达从实验室到临床转化的一个绝佳范例。
Indian J Dermatol Venereol Leprol. 2023 Aug 23:1-3. doi: 10.25259/IJDVL_362_2023.
4
A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.一项前瞻性研究，探讨了 STAT1、3、6 在结节性痒疹皮损中的表达及其免疫发病机制和治疗意义。
J Cosmet Dermatol. 2022 Sep;21(9):4009-4015. doi: 10.1111/jocd.14709. Epub 2021 Dec 29.
5
Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.低剂量沙利度胺治疗台湾特发性结节性瘙痒症患者
J Dermatol. 2007 Apr;34(4):237-42. doi: 10.1111/j.1346-8138.2007.00260.x.
6
Dupilumab for pediatric prurigo nodularis: A case report.度普利尤单抗治疗儿童结节性痒疹：一例报告
Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.
7
Dupilumab for prurigo nodularis: Case series and review of the literature.度普利尤单抗治疗结节性痒疹：病例系列及文献综述
Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.
8
Use of lenalidomide in treating refractory prurigo nodularis.来那度胺在治疗难治性结节性痒疹中的应用。
J Drugs Dermatol. 2013 Mar;12(3):360-1.
9
Recalcitrant prurigo nodularis treated successfully with dupilumab.度普利尤单抗成功治疗顽固性结节性痒疹。
JAAD Case Rep. 2019 May 8;5(5):471-473. doi: 10.1016/j.jdcr.2019.03.016. eCollection 2019 May.
10
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.沙利度胺治疗人类免疫缺陷病毒感染患者的结节性痒疹：疗效及神经病变风险
Arch Dermatol. 2004 Jul;140(7):845-9. doi: 10.1001/archderm.140.7.845.

引用本文的文献

1
Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases.托法替布成功用于儿童结节性痒疹：4例报告
Indian J Dermatol. 2025 Mar-Apr;70(2):102-104. doi: 10.4103/ijd.ijd_842_24. Epub 2025 Feb 27.
2
Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.乌帕替尼治疗难治性结节性痒疹：一项前瞻性队列研究。
Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546.
3
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.结节性痒疹：发病机制与潜在治疗靶点。

本文引用的文献

1
A Prospective Study Examining the Effect of Selected Topical and Systemic Drugs on Pruritus Grading System Score and STAT 6 Expression in Patients of Prurigo Nodularis.一项前瞻性研究，考察特定局部和全身用药对结节性痒疹患者瘙痒分级系统评分及信号转导和转录激活因子6（STAT 6）表达的影响。
Indian J Dermatol. 2021 Nov-Dec;66(6):638-644. doi: 10.4103/ijd.ijd_341_21.
2
A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.一项前瞻性研究，探讨了 STAT1、3、6 在结节性痒疹皮损中的表达及其免疫发病机制和治疗意义。
J Cosmet Dermatol. 2022 Sep;21(9):4009-4015. doi: 10.1111/jocd.14709. Epub 2021 Dec 29.
3
Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.
4
Molecular mechanisms of pruritus in prurigo nodularis.结节性痒疹瘙痒的分子机制。
Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.
Successful treatment of recalcitrant nodular prurigo with tofacitinib.
托法替布成功治疗顽固性结节性痒疹。
Clin Exp Dermatol. 2020 Oct;45(7):918-920. doi: 10.1111/ced.14320. Epub 2020 Jul 18.
4
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.观察性分析在顽固结节性痒疹中应用小剂量沙利度胺。
Clin Exp Dermatol. 2020 Jan;45(1):92-96. doi: 10.1111/ced.14015. Epub 2019 Jun 21.